Review Article
A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma
Table 1
Background information on US FDA-approved PD-1/PD-L1 inhibitors for the treatment of urothelial carcinoma.
| Target | Generic name | Antibody class | Trade name | Development name(s) | Company | Recommended dose and schedule | Date of approval |
| PD-1 | Nivolumab | Human IgG4 | Opdivo | BMS-936558, MDX-1106, ONO-4538 | Bristol-Myers Squibb Co. | 240 mg, every 2 weeks | 2 Feb. 2017 | Pembrolizumab | Humanized IgG4 | Keytruda | MK-3475, lambrolizumab | Merck and Co. Inc. | 200 mg, every 3 weeks | 18 May 2017 | PD-L1 | Atezolizumab | Human IgG1k | Tecentriq | MPDL3280A, RG7446 | Genentech Inc. | 1200 mg, every 3 weeks | 18 May 2016 | Durvalumab | Humanized IgG1k | Imfinzi | MEDI-4736 | AstraZeneca UK Limited | 10 mg/kg, every 2 weeks | 1 May 2017 | Avelumab | Human IgG1 | Bavencio | MSB0010718C, MSB0010682 | EMD Serono Inc. | 10 mg/kg, every 2 weeks | 9 May 2017 |
|
|
All are for the patients with locally advanced or metastatic urothelial carcinoma and who has the prior platinum-based chemotherapy.
|